DUALITYBIO-B (09606) announced its interim results for 2025, reporting revenue of approximately 1.229 billion yuan, representing a year-over-year increase of 22.9%. Gross profit reached approximately 589 million yuan, up 3.73% compared to the same period last year. Research and development expenses totaled approximately 349 million yuan, down 7.5% year-over-year. Adjusted profit for the period was approximately 146 million yuan, marking a 14.2% increase year-over-year.

According to the announcement, the revenue increase was primarily driven by the expansion of research and development activities through external licensing and collaboration agreements. Since the beginning of 2025, the group has achieved encouraging progress in both pipeline development and business operations.

To date, the group has enrolled over 2,600 patients across all clinical trials, with more than 600 patients enrolled in the first half of 2025 alone (approximately 50% of patients are located in the United States, European Union, Australia, and other regions outside mainland China).

The company plans to accelerate the global development and commercialization process of its clinical-stage projects to unlock their commercial value. It will also continue to strengthen its expertise in global research, clinical development, and regulatory affairs to drive the future wave of ADC innovation.

By leveraging the company's innovative capabilities and value-added partnerships, the group aims to fully unlock the potential of ADCs and revolutionize treatment paradigms for oncology, autoimmune diseases, and other therapeutic areas.